Cargando…

PB2265: OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH B AND PLASMA CELL MALIGNANCIES DURING THE THIRD WAVE IN ARGENTINA: A SINGLE CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Gelo, O., Korin, L., Ayala, L., Cranco, S., Babuin, E., Vitriu, A., Ochoa, P., Fuente, M. L., Tartas, N., Alderete, M., Flagel, S., Sosa, C., Gazzaneo, M. A., Zylberman, M., Díaz Couselo, F., Irrazábal, C., Custidiano, M. D. R., Sánchez Ávalos, J., Foncuberta, M. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429500/ http://dx.doi.org/10.1097/01.HS9.0000851888.50664.55

Ejemplares similares

P1275: PERCENTAGE OF TUMOR INFILTRATING T LYMPHOCYTES MEASURED BY FLOW CYTOMETRY AT DIAGNOSIS PREDICTS SURVIVAL AFTER SALVAGE CHEMOTHERAPY IN RELAPSED/ REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PATIENTS.
por: Korin, L., et al.
Publicado: (2022)

P041: Low percentage of T lymphocytes in Hodgkin’s Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
por: Korin, Laura, et al.
Publicado: (2022)

PB2265: RISK FACTORS FOR DISEASE PROGRESSION OF MYCOSIS FUNGOIDES AND SÉZARY SYNDROME IN EAST ASIAN POPULATION
por: Wu, Huai-Chueh Gem, et al.
Publicado: (2023)

PB1865: SINGLE-COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG).
por: Pagano Vilar, C., et al.
Publicado: (2022)

PB1945: CLINICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN WITH DIAMOND-BLACKFAN ANEMIA (DBA): A SINGLE CENTER EXPERIENCE IN ARGENTINA
por: Mininni, M. F., et al.
Publicado: (2022)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
por: Navickas, A., et al.
Publicado: (2022)

Retrospective Multicenter Real-Life Study on the First-Line Treatment of Classical Hodgkin Lymphoma in Argentina
por: Mahuad, Carolina, et al.
Publicado: (2022)

PReS-FINAL-2265: Tuberculosis in pediatric patients who are receiving anti-TNF agents
por: Calzada-Hernández, J, et al.
Publicado: (2013)

P013: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
por: Laura, Korin, et al.
Publicado: (2022)

2265. The Changing Landscape of AIDS Defining CNS Infections in S. Alberta, Canada Over 30 Years
por: Lang, Raynell, et al.
Publicado: (2018)

2265. Immunocompromised Patients, Compromised Guidelines? Practice Patterns of Managing Asymptomatic Bacteriuria in Immunocompromised Patients
por: Moore, Jacqueline, et al.
Publicado: (2023)

2265 Effect of dietary approaches to stop hypertension (DASH) diet on hemodynamic markers in advanced heart failure patients
por: Sattler, Elisabeth L. P., et al.
Publicado: (2018)

Catheter-Related Acremonium kiliense Fungemia in a Patient with Ulcerative Colitis under Treatment with Infliximab
por: Díaz-Couselo, Fernando A., et al.
Publicado: (2011)

PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA
por: Soussain, C., et al.
Publicado: (2022)

PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
por: De La Fuente, A., et al.
Publicado: (2022)

Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia
por: Ruiz, María Sol, et al.
Publicado: (2018)

OTOF mutation analysis with massively parallel DNA sequencing in 2,265 Japanese sensorineural hearing loss patients
por: Iwasa, Yoh-ichiro, et al.
Publicado: (2019)

2265. Clinical Outcomes with Single vs. Combination Antibiotic Therapy in the Treatment of Burkholderia cepacia complex Bacteremia and Pneumonia
por: George, G Taylor A, et al.
Publicado: (2019)

PB1836: ACUTE MYELOID LEUKEMIA IN OLDER ADULTS IN RESOURCE CONSTRAINT SETTING: SINGLE CENTER DATA FROM SOUTH INDIA
por: Paul, M., et al.
Publicado: (2022)

PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT
por: Faulkner, L., et al.
Publicado: (2022)

PB1976: CRISPR-CAS9 KNOCKOUT SCREEN IDENTIFIES RNA MODIFICATION ENZYMES ESSENTIAL FOR CELL SURVIVAL IN MULTIPLE MYELOMA
por: Zhao, D., et al.
Publicado: (2022)

PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION
por: Gore, L., et al.
Publicado: (2022)

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, L., et al.
Publicado: (2022)

PB2259: MONOCYTE’S INVOLVEMENT IN INFLAMMATORY RESPONSE IN COVID-19 INFECTION IN CHRONIC RENAL DISEASE
por: Bumbea, V., et al.
Publicado: (2022)

PB2001: A LOOK INTO THE REAL WORLD: PICTURE OF NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE TREATED PATIENTS IN THE FRONTLINE SETTING. CARINAE STUDY
por: de Arriba de la Fuente, F., et al.
Publicado: (2022)

PB1752: ANALYSIS OF HLA-PEPTIDE BINDING POCKETS IN PATIENTS WITH ACUTE LEUKEMIA UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION
por: Boukouaci, W., et al.
Publicado: (2022)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB2287: END OF LIFE TRANSFUSIONS IN PATIENTS WITH AN ONCOLOGICAL DIAGNOSIS
por: Duque, L., et al.
Publicado: (2022)

PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
por: Koreth, J., et al.
Publicado: (2022)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

PB2139: A REAL-WORLD OUTCOME OF NEWLY DIAGNOSED PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH 6 CYCLES OF R-CHOEP-14 AND 2 CYCLES OF DHAP FOLLOWED BY AN AUTOLOGOUS STEM CELL TRANSPLANT
por: Tan Tsen Chuen, J., et al.
Publicado: (2022)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
por: Raffoux, E., et al.
Publicado: (2022)

PB1845: ACUTE MYELOID LEUKEMIA IN THE ELDERLY: A MULTICENTER EXPERIENCE IN COLOMBIA, ON BEHALF OF ACHO’S RENEHOC INVESTIGATORS
por: Sossa-Melo, C., et al.
Publicado: (2022)

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
por: Jurczak, W., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3oqk24fit87167h4tpori6ggpd